Clinical Scorecard: Video: Fellow Eye Data Supports GA Clinical Trial Design
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic Atrophy (GA) |
| Key Mechanisms | Pegcetacoplan (C3 inhibitor) reduces geographic atrophy growth rates. |
| Target Population | Patients with bilateral geographic atrophy. |
| Care Setting | Clinical trials and retinal specialty practices. |
Key Highlights
- Fellow eyes grow at similar rates to sham-treated eyes.
- Validates the use of fellow eyes as control groups in clinical trials.
- Pegcetacoplan's effect in reducing GA increases over time.
- Early intervention with C3 inhibitors is recommended.
Guideline-Based Recommendations
Diagnosis
- Assess bilateral geographic atrophy through clinical examination and imaging.
Management
- Consider pegcetacoplan treatment for eligible patients with bilateral GA.
Monitoring & Follow-up
- Monitor growth rates of geographic atrophy in both eyes.
Risks
- Potential for disease progression if treatment is delayed.
Patient & Prescribing Data
Patients with bilateral geographic atrophy.
Intervention with pegcetacoplan should be considered early to maximize retinal preservation.
Clinical Best Practices
- Utilize fellow eyes as control groups in clinical trials for GA.
- Encourage early treatment initiation with C3 inhibitors.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
